{"id":"W4392805481","doi":"10.1007/s10637-024-01428-0","title":"A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors","year":2024,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Selumetinib; Medicine; Pembrolizumab; Adverse effect; Internal medicine; MEK inhibitor; Gastroenterology; Pharmacology; Urology; Oncology; Cancer; Colorectal cancer; MAPK/ERK pathway; Immunotherapy; Chemistry; Kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018898,0.0001171427,0.0001480902,0.0000578826,0.00003761091,0.00001934462,0.0001179449,0.00004345272,0.000009965936],"category_scores_gemma":[0.0002474018,0.0000759117,0.00006967024,0.0001938325,0.00009685269,0.00001043594,0.00002815952,0.00006372026,0.000001674134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001730706,"about_ca_system_score_gemma":0.0009590286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001336786,"about_ca_topic_score_gemma":0.0000384059,"domain_scores_codex":[0.9990991,0.00005758246,0.0002860961,0.0002331821,0.0001944383,0.0001295697],"domain_scores_gemma":[0.9995423,0.00008113537,0.00009710593,0.0001432359,0.0000721686,0.00006403722],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03539273,0.0008951553,0.00006162471,0.000444747,0.0001918021,0.00001243899,0.001358224,0.0007503036,0.9209279,0.01967993,0.008557369,0.01172778],"study_design_scores_gemma":[0.1028848,0.005119793,0.00009195527,0.0003275918,0.00008042823,0.00003314646,0.0001983462,0.002236943,0.8596213,0.01113792,0.01797916,0.0002886105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965476,0.0001204996,0.001025232,0.000876195,0.0002565289,0.0009080905,0.00008178551,0.00001067304,0.0001733575],"genre_scores_gemma":[0.994599,0.000004824974,0.003466306,0.0001818723,0.0001860359,0.0001736994,0.0002169922,0.0000195797,0.001151655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0674921,"threshold_uncertainty_score":0.3095589,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02116369759197948,"score_gpt":0.2994471895682759,"score_spread":0.2782834919762964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}